INT66544

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 1996
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 23
Total Number 24
Disease Relevance 8.33
Pain Relevance 2.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Igf1) extracellular region (Igf1)
Anatomy Link Frequency
fibroblast 2
plasma 1
muscle 1
spinal cord 1
brain 1
Igf1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Spinal cord 4 100.00 Very High Very High Very High
cytokine 57 99.62 Very High Very High Very High
Analgesic 9 99.56 Very High Very High Very High
Inflammation 68 99.42 Very High Very High Very High
Antinociceptive 2 97.36 Very High Very High Very High
Clonidine 2 96.72 Very High Very High Very High
Central nervous system 40 95.28 Very High Very High Very High
Somatostatin 13 94.96 High High
Hippocampus 13 94.24 High High
cerebral cortex 25 93.52 High High
Disease Link Frequency Relevance Heat
Brain Injury 5 100.00 Very High Very High Very High
Injury 87 99.92 Very High Very High Very High
Cancer 71 99.64 Very High Very High Very High
INFLAMMATION 75 99.42 Very High Very High Very High
Insulin Resistance 11 98.52 Very High Very High Very High
Acromegaly 78 98.48 Very High Very High Very High
Diabetes Mellitus 81 96.88 Very High Very High Very High
Chronic Renal Failure 28 96.32 Very High Very High Very High
Acidosis 6 96.00 Very High Very High Very High
Critical Illness 83 95.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The implication of this is that for intraventricularly injected IGF-1 to be centrally effective it either interacts with receptors or compartments that are immediately around the ventricular system or works at deep active sites at the low levels indicated by the 30–180 min 125I-IGF-1 plateaux (Fig. 9).
IGF-1 Binding (interacts) of in ventricular system
1) Confidence 0.46 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1190198 Disease Relevance 0.26 Pain Relevance 0.11
Recent work has focused on the potential for a direct interaction between the GH–IGF-I axis and the immune system via the common cellular receptor.
IGF-I Binding (interaction) of in immune system
2) Confidence 0.37 Published 2007 Journal Crit Care Section Body Doc Link PMC2206515 Disease Relevance 0.34 Pain Relevance 0.28
Self- or partner-administration of lanreotide was associated with both IGF-1 and GH control in many patients with acromegaly (73.1% of switch patients and 30.4% of “other” patients at week 24 or early termination versus 63.3% and 4.0% at week 0, respectively; Table 2).
IGF-1 Binding (associated) of associated with acromegaly
3) Confidence 0.36 Published 2009 Journal Pituitary Section Body Doc Link PMC2855862 Disease Relevance 0.18 Pain Relevance 0
As one might expect, the duration of acromegaly was longer in switch than in “other” patients, since they were previously on a fixed dose of SSA, and their IGF-1 and GH control was maintained with lanreotide treatment in this study.
IGF-1 Binding (maintained) of associated with acromegaly
4) Confidence 0.36 Published 2009 Journal Pituitary Section Body Doc Link PMC2855862 Disease Relevance 0.23 Pain Relevance 0
In normal muscle, binding of insulin or insulin-like growth factor (IGF)-1 to their receptors increases the activities of PI3K and its downstream target, Akt.
IGF Binding (binding) of in muscle
5) Confidence 0.36 Published 2007 Journal Pediatr Nephrol Section Body Doc Link PMC2259254 Disease Relevance 0.99 Pain Relevance 0
Our data provide evidence that the IGF-I system within the spinal cord may serve as a target for novel analgesics.
IGF-I Binding (target) of in spinal cord associated with analgesic and spinal cord
6) Confidence 0.36 Published 1996 Journal Brain Res. Section Abstract Doc Link 8930378 Disease Relevance 0.17 Pain Relevance 0.49
Distribution of IGF-1 radioactivity within the CSF system
IGF-1 Binding (radioactivity) of
7) Confidence 0.35 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1190198 Disease Relevance 0 Pain Relevance 0
Self- or partner-administration of lanreotide is generally well tolerated and associated with IGF-1 and GH control in many lanreotide-naïve patients with acromegaly.



IGF-1 Binding (associated) of associated with acromegaly
8) Confidence 0.35 Published 2009 Journal Pituitary Section Abstract Doc Link PMC2855862 Disease Relevance 0.16 Pain Relevance 0.03
Interactions between the IGF-I and ER-?
IGF-I Binding (Interactions) of
9) Confidence 0.35 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC468665 Disease Relevance 0.39 Pain Relevance 0
For GH and IGF-I delivery, recombinant human GH or IGF-I (Genentech, South San Francisco, CA) was dissolved in sterile saline at a concentration of 0.25 mg/mL.
IGF-I Binding (recombinant) of
10) Confidence 0.35 Published 2007 Journal BMC Physiol Section Body Doc Link PMC1851714 Disease Relevance 0.16 Pain Relevance 0.15
Furthermore, it is interesting that IGF-I alone positively influenced healing in tissues from both ambulatory and hindlimb unloaded animals, while combined GH and IGF-I only had a positive affect on tissues from HU animals.
IGF-I Binding (combined) of in hindlimb
11) Confidence 0.35 Published 2007 Journal BMC Physiol Section Body Doc Link PMC1851714 Disease Relevance 0 Pain Relevance 0
Although 125I-IGF-1 concentrations were somewhat high in the ventricular and intravenous infusates, it would be diluted to tracer levels in plasma within seconds as it mixes in the circulating blood and binds to plasma proteins such as the IGFBP's.
125I-IGF-1 Binding (concentrations) of in plasma
12) Confidence 0.31 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1190198 Disease Relevance 0.12 Pain Relevance 0.05
Microautoradiography indicated that 3H-IGF-1 was also present in the corpus callosum and its ventral extension, the external capsule, plus the perivascular (Virchow-Robin) spaces that surround the penetrating arteries and arterioles of the cortex 30 min after ending the infusion.
3H-IGF-1 Binding (present) of in ventral
13) Confidence 0.31 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1190198 Disease Relevance 0.40 Pain Relevance 0.12
Intraventricular IGF-1 delivery following brain injury
IGF-1 Binding (injury) of in brain associated with brain injury
14) Confidence 0.31 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1190198 Disease Relevance 0.43 Pain Relevance 0.11
Inflammatory cytokines (IL-6 and IL-10), IGF-I and its binding proteins (IGFBP-I, IGFBP-III) were analysed from blood samples, drawn between days 3 and 7 as well as between days 8 and 10 after ICU admission.
IGF-I Spec (analysed) Binding (binding) of in blood associated with inflammation and cytokine
15) Confidence 0.23 Published 2010 Journal Crit Care Section Body Doc Link PMC2911767 Disease Relevance 0.93 Pain Relevance 0.14
Impairment of IGF-I may be due to inflammation-induced upregulation of high-affinity IGFBP-1 which prevents IGF-I receptor binding [32].
IGF-I Binding (binding) of associated with inflammation
16) Confidence 0.22 Published 2010 Journal Crit Care Section Body Doc Link PMC2911767 Disease Relevance 1.08 Pain Relevance 0.29
For example, epidermal growth factor, insulin-like growth factor I and transforming growth factor-?
insulin-like growth factor I Binding (example) of
17) Confidence 0.19 Published 2008 Journal Acta Histochemica et Cytochemica Section Body Doc Link PMC2532488 Disease Relevance 0 Pain Relevance 0
Tarnawski et al. [28] previously reported that rebamipide significantly upregulated the proangiogenic genes encoding vascular endothelial growth factor (VEGF), heparin binding epidermal growth-like factor (HB-EGF), fibroblast growth factor receptor-2 (FGFR2), and cyclooxygenase-2 (Cox2), as well as growth promoting genes, including insulin growth factor-1 (IGF-1).
IGF-1 Binding (binding) of in fibroblast
18) Confidence 0.18 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2243244 Disease Relevance 0.45 Pain Relevance 0.07
Tarnawski et al. [28] previously reported that rebamipide significantly upregulated the proangiogenic genes encoding vascular endothelial growth factor (VEGF), heparin binding epidermal growth-like factor (HB-EGF), fibroblast growth factor receptor-2 (FGFR2), and cyclooxygenase-2 (Cox2), as well as growth promoting genes, including insulin growth factor-1 (IGF-1).
insulin growth factor-1 Binding (binding) of in fibroblast
19) Confidence 0.18 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2243244 Disease Relevance 0.45 Pain Relevance 0.07
and IGF-1 deficits and do not occur to a significant degree in type 2
IGF-1 Neg (not) Binding (occur) of
20) Confidence 0.15 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2323445 Disease Relevance 0.67 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox